Literature DB >> 18946741

The promise and perils of an Alzheimer disease vaccine: a video debate.

Dave Morgan1, Gary Landreth, Paula Bickford.   

Abstract

Alzheimer's disease (AD) is a critical health care problem that has considerable social and economic impact on society. Effective treatments have been elusive. One major causal factor for the disease is believed to be the deposition of amyloid fibrils in the brain, which ultimately leads to neurodegeneration and cognitive dysfunction. Based on the amyloid hypothesis of Alzheimer's disease, many therapies presently target the amyloid beta (Abeta) peptide, the monomeric protein fragment that assembles to form fibrils. This video article takes the form of a debate between Dr. Morgan and Dr. Landreth on the merits and drawbacks of an Alzheimer's disease vaccine. Click on Supplemental Material to watch the streaming video.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18946741     DOI: 10.1007/s11481-008-9132-4

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  14 in total

1.  Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Authors:  J-M Orgogozo; S Gilman; J-F Dartigues; B Laurent; M Puel; L C Kirby; P Jouanny; B Dubois; L Eisner; S Flitman; B F Michel; M Boada; A Frank; C Hock
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

2.  The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Marcus A Westerman; Deirdre Cooper-Blacketer; Ami Mariash; Linda Kotilinek; Takeshi Kawarabayashi; Linda H Younkin; George A Carlson; Steven G Younkin; Karen H Ashe
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

3.  Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice.

Authors:  M N Gordon; D L King; D M Diamond; P T Jantzen; K V Boyett; C E Hope; J M Hatcher; G DiCarlo; W P Gottschall; D Morgan; G W Arendash
Journal:  Neurobiol Aging       Date:  2001 May-Jun       Impact factor: 4.673

4.  Neuroanatomical abnormalities in behaviorally characterized APP(V717F) transgenic mice.

Authors:  J C Dodart; C Mathis; J Saura; K R Bales; S M Paul; A Ungerer
Journal:  Neurobiol Dis       Date:  2000-04       Impact factor: 5.996

5.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

6.  A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease.

Authors:  G Chen; K S Chen; J Knox; J Inglis; A Bernard; S J Martin; A Justice; L McConlogue; D Games; S B Freedman; R G Morris
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

7.  Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

Authors:  Donna M Wilcock; Amyn Rojiani; Arnon Rosenthal; Gil Levkowitz; Sangeetha Subbarao; Jennifer Alamed; David Wilson; Nedda Wilson; Melissa J Freeman; Marcia N Gordon; Dave Morgan
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

Review 8.  Active and passive immunotherapy for neurodegenerative disorders.

Authors:  David L Brody; David M Holtzman
Journal:  Annu Rev Neurosci       Date:  2008       Impact factor: 12.449

9.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Authors:  Christoph Hock; Uwe Konietzko; Johannes R Streffer; Jay Tracy; Andri Signorell; Britta Müller-Tillmanns; Ulrike Lemke; Katharina Henke; Eva Moritz; Esmeralda Garcia; M Axel Wollmer; Daniel Umbricht; Dominique J F de Quervain; Marc Hofmann; Alessia Maddalena; Andreas Papassotiropoulos; Roger M Nitsch
Journal:  Neuron       Date:  2003-05-22       Impact factor: 17.173

10.  Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice.

Authors:  Jukka Puoliväli; Jun Wang; Taneli Heikkinen; Matti Heikkilä; Tero Tapiola; Thomas van Groen; Heikki Tanila
Journal:  Neurobiol Dis       Date:  2002-04       Impact factor: 5.996

View more
  1 in total

1.  Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease.

Authors:  Ashley D Reynolds; David K Stone; Jessica A L Hutter; Eric J Benner; R Lee Mosley; Howard E Gendelman
Journal:  J Immunol       Date:  2010-01-29       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.